Drug intelligence / Profile preview

ADCE-B05

Development stage: Phase 1
Lead developer: Adcendo
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
Administration: Intravenous

Overview

ADCE-B05 is an antibody-drug conjugate (ADC) being developed by Adcendo for the treatment of squamous cell carcinoma. It is currently in preclinical development, with plans for investigational new drug (IND) submission to the US FDA anticipated in the second half of 2025. The specific molecular target and mechanism of action have not been publicly disclosed as of early 2025. Adcendo, a biotechnology company specializing in ADCs for underserved cancers, is advancing this candidate as part of its pipeline focused on innovative therapies for solid tumors.

Other names: ADCE B05

Targets

F3 (Tissue factor)TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on ADCE-B05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADCE-B05.

Explore the full profile